Department of Medicine 3 – Rheumatology and Immunology

Regulation of plasma cell homeostasis and antibody secretion through modulation of autophagy and endoplasmic reticulum stress by Trk-fused-gene (TFG) (2022) Thomas J, Steinmetz T, Mielenz D Conference contribution Using surface-bound IgG-catcher constructs to identify antigen-specific plasma cells (2022) Kilo J, Roth E, Jäck HM, Schulz S Conference contribution Microbiota-derived propionate modulates megakaryopoiesis and platelet function (2022) Schmid E, Dürholz K, Frech M, Otterbein N, Lucas S, Rauh M, Schett G, et al. Conference contribution Metabolic regulation of plasma cell generation in germinal centers through EFhd2 (2022) Weckwerth L, Gottwald A, Mielenz D Conference contribution Short-term Safety of COVID-19 Vaccination in Systemic Sclerosis Patients: Report from a Global Patient-Reported E-survey (2022) Thakare D, Naveen R, Pauling J, Ahmed S, Wincup C, Del Papa N, Sambataro G, et al. Conference contribution Breakthrough Infections in COVID-19 Vaccinated Patients with Systemic Sclerosis: A Survival Analysis from a Multicenter International Patient-Reported Survey (2022) Ahmed S, Naveen R, Pauling J, Thakare D, Wincup C, Del Papa N, Sambataro G, et al. Conference contribution Vaccine Hesitancy Among Patients with Idiopathic Inflammatory Myopathies and Rheumatic Diseases in 2021-2022: A Comparative Analysis of COVID-19 Vaccination in Autoimmune Diseases Surveys (2022) Naveen R, Joshi M, Sen P, Agarwal V, Shinjo S, Kardes S, Lilleker JB, et al. Conference contribution COVID-19 Vaccination in Autoimmune Diseases Study: Vaccine Safety in Rheumatoid Arthritis (2022) Naveen R, Parodis I, Joshi M, Sen P, Kim M, Agarwal V, Kardes S, et al. Conference contribution COVID-19 Vaccination-related Short-term Adverse Events in Patients with Idiopathic Inflammatory Myositis and Autoimmune Multimorbidity: Results from the COVID-19 Vaccination in Autoimmune Diseases Survey (2022) Dey M, Naveen R, Nikiphorou E, Sen P, Lilleker JB, Agarwal V, Kardes S, et al. Conference contribution Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study) (2022) Rech J, Kleyer A, Ostergaard M, Hagen M, Mendez LV, Tascilar K, Krönke G, et al. Conference contribution